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Abstract: Measures to reduce tuberculosis (TB) transmission in 
communities through active case finding have generally been 
disappointing. It is becoming increasingly apparent that TB may have a 
culture-positive subclinical phase 4-6 times as long as the clinical 
phase. Our current framework relates TB transmission to symptoms caused 
by the disease.  We propose that in the subclinical phase it is possible 
that transmission may be facilitated by causes of chronic or acute cough 
unrelated to TB.  This conceptual shift has significant implications for 
TB epidemiology and control. 
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Body (886 words 12 ref) 
Mycobacterium tuberculosis (Mtb) is the leading cause of death from an infectious disease 
globally and is estimated to have infected approximately 25% of the world’s population.
1
  To 
achieve the dramatic reductions in tuberculosis (TB) incidence required to meet consensus 
targets, interventions that minimise Mtb transmission will be critical.  
The long infectious period of TB is becoming increasingly apparent and is likely a major 
factor in the pathogen’s success. If granulomatous control fails, pulmonary TB typically 
progresses into a bronchogenic pneumonia (sometimes visible radiographically), resulting in 
bacilli in respiratory secretions (the basis of diagnosis via sputum examination).
2
 The 
development of cough facilitates transmission and, along with other symptoms, increases 
subjective awareness of illness, encouraging healthcare-seeking behaviour. 
Prevalence/notification ratios suggest the duration of culture-positive disease prior to passive 
case detection may be as long as 18 months, which corresponds with recent evidence that the 
emergence of a TB transcriptional profile in blood is detectable over a similar period.
3-5
 
However, patients often report symptoms only in the 2-3 months before diagnosis.
6
 
The premise of active case finding (ACF) for TB is to identify individuals with infectious TB 
who have not yet sought care, thus treating disease earlier, reducing risk of death for 
individuals and, critically, the period of transmission in the population. Active case finding 
often uses symptom screening (e.g. cough, fever, night sweats and weight loss) to decide who 
to test for TB. However, in recent TB prevalence surveys in Asia, TB symptoms were not 
reported by a majority (up to 80%) of individuals with bacteriologically confirmed infectious 
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TB.
5
  It is perhaps not surprising that a systematic review of ACF studies found limited 
evidence for benefit to individual or population outcomes.
7
  One explanation for this may be 
that TB symptom screening, misses individuals who either don’t report or have alternative 
explanations for their symptoms, but nevertheless contribute to transmission. Their 
contribution may be particularly important if they cycle through periods of higher 
infectiousness, or have significant social contact. Conceptual frameworks that only link TB 
transmission to symptoms caused by TB, omitting the possibility of transmission by those 
with no or unrelated respiratory symptoms, may lack utility in understanding TB 
epidemiology and designing interventions. 
Transmission of TB occurs via aerosolisation of infectious droplet nuclei, which are most 
efficiently produced by coughing.  Infectiousness depends on both droplet nuclei production 
rates and concentration of bacilli in respiratory secretions. Frequency of spontaneous 
coughing in those without respiratory pathology is low and therefore individuals with 
subclinical TB (with less advanced disease) have traditionally been considered uninfectious.   
However, TB transmission during the subclinical phase may be enhanced by either acute or 
chronic coughing resulting from conditions unrelated to TB pathology. The prevalence of 
chronic productive cough (present for at least three months of the year for at least two 
consecutive years) is 10-15% in European countries.
8
  This prevalence may be greater in 
populations with high levels of indoor, outdoor or occupational air pollution (e.g. 50% of 
miners without silicosis report chronic cough), which are commoner in high-burden TB 
countries. Individuals with chronic cough may cough 50 times per hour in contrast to twice 
per hour in those without respiratory pathology.
9
  A systematic review of TB diagnostic delay 
identified chronic cough as a major contributor to delay, potentially due to patient 
normalization to this symptom.
6
  No studies have directly explored the contribution of 
chronic cough to TB transmission, however household contacts of smokers with TB have 
consistently been shown to be at increased risk of latent TB infection.
10
  Although this may 
reflect the effect of smoke exposure on the innate immune system, it could also be accounted 
for by increased chronic cough in smokers.  Bouts of acute cough may also contribute to 
transmission. The average TB case might be expected to have two or three episodes of upper 
respiratory tract infection (URTI) during their period of subclinical disease (higher if co-
habiting with young children).
11
  After some viral URTIs, as many as 16% of people with no 
prior respiratory pathology cough for more than two weeks.
12
  TB might piggyback 
transmission with viral URTIs, which could be a contributing factor to the seasonality of TB.  
The potential for the long period of subclinical TB to contribute to transmission (four to six 
times as long as the recognised ‘symptomatic’ period) and be amplified by chronic cough and 
acute cough is illustrated in the Figure. This has implications for TB epidemiology and 
control. Screening approaches for ACF in certain populations may need to rely more on 
radiography or utilize screening questionnaires focussing on chronic respiratory symptoms, 
regardless of cause. Common causes of chronic cough, both infectious and non-infectious, 
may provide additional targets for intervention in TB endemic communities and control 
measures for viral URTI may also benefit TB control. 
We need to develop a better understanding of the importance of these factors. Mathematical 
modelling provides tools to explore the implications of pre-clinical natural history for 
epidemiology and control. However, further empirical studies are needed to demonstrate and 
quantify the contribution of the subclinical period to TB transmission, which may be 
facilitated by the increasing use of whole genome sequencing.  
We live an era where accelerated progress towards ending TB is demanded, but old 
approaches repeatedly fail to deliver. Fresh thinking is required, and a better understanding of 
TB transmission during the subclinical phase could open new avenues of attack.  
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 Figure: Transmission potential in subclinical and clinical TB 
Cartoons show how infectiousness may change over time in two scenarios.  Infectiousness on 
the y-axis is considered to be a function of the rate of droplet nuclei production (through 
coughing) and the concentration of bacilli in respiratory secretions.  The duration of 
subclinical disease (culture positive with baseline symptoms) is 12 months and clinical 
disease with symptoms related to TB is three months.  Area under curve represents 
transmission potential.  Identifying individuals as early as possible in clinical phase of TB 
may still miss transmission in the subclinical phase.  
a) Shows a scenario in which baseline symptoms are minimal with 3 episodes of upper 
respiratory tract infection (URTI). 
b) Shows a scenario in which a chronic cough unrelated to TB is present with 3 episodes of 
URTI.  
 
